Boehringer Ingelheim GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: March 9, 2016
Pages: 122
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B008AD73208EN
Leaflet:

Download PDF Leaflet

Boehringer Ingelheim GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Boehringer Ingelheim GmbH (Boehringer) is a pharmaceutical company, which carries out research, development, manufacture and sale of pharmaceuticals. The company offers a wide range of products including prescription medicines, consumer health care products, animal health care products and biopharmaceuticals. Its products are used in the treatment of central nervous system disorders, respiratory diseases, cardiovascular diseases, metabolic disorders, cancer, urological and viral conditions, among others. The company focuses on the research, development, manufacture and marketing of new drugs of therapeutic value for human and veterinary medicine. Boehringer operates globally through affiliates and is headquartered in Ingelheim, Germany.

Boehringer Ingelheim GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Medical Devices Deals, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis
Boehringer Ingelheim To Acquire Global Rights To FX125L And Somatotaxin Portfolio From Funxional Therapeutics
Boehringer Ingelheim Plans To Acquire OTC Brands In India
Boehringer Ingelheim Acquires PDE2 Inhibitors Platform From biocrea
Boehringer Ingelheim Acquires Fremont Facility From Amgen
Venture Financing
Pcovery Raises USD4 Million in Venture Financing
Eyevensys Raises Funds In Second Round Of Financing
ArmaGen Technologies Raises US$17 Million In Series A Financing
Partnerships
Boehringer May Enter into Agreement with AbbVie
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center
Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement
Boehringer Ingelheim Enters into Partnership with Circuit Therapeutics
Boehringer Ingelheim Terminates Agreement with Vitae Pharma
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics
Boehringer Ingelheim Pharma Enters into Research Agreement with Sutter Health
Artes Biotech Enters into Agreement with Boehringer Ingelheim
Boehringer Ingelheim Extends Agreement with VTU Technology
Boehringer Ingelheim Extends Research Agreement with BioMed X
Eli Lilly Amends Co-Promotion Agreement with Boehringer Ingelheim
Boehringer Ingelheim Terminates Co-Marketing Agreement with Pfizer for Spiriva
Hydra Biosciences Enters Into R&D Agreement With Boehringer Ingelheim
Crystal Biosciences Enters Into Agreement With Boehringer Ingelheim To Discover And Develop Therapeutic Antibodies
Circuit Therapeutics Enters Into Research Agreement With Boehringer Ingelheim For Drug Discovery
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim
Beactica Expands Drug Discovery Agreement With Boehringer Ingelheim
Diaxonhit Enters Into Research Agreement With Boehringer Ingelheim For Epitope Targets
Boehringer Ingelheim And Shanghai Zhangjiang Biotech Form R&D Joint Venture
Novation Pharma Enters into Research Agreement with Boehringer Ingelheim
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets
Eli Lilly Terminates Co-Development Agreement With Boehringer For LY2605541
Boehringer Ingelheim Enters Into Research Agreement With ETH Zurich
Ablynx Extends Co-development Agreement With Boehringer Ingelheim For Nanobody Therapeutics
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies
Eli Lilly Enters Into Co-Promotion Agreement With Boehringer Ingelheim For Humalog And Linagliptin
Nuevolution Enters Into Co-Development Agreement With Boehringer Ingelheim
Pfenex Enters Into Collaboration With Boehringer Ingelheim
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim
Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim
Hepregen Extends Technology Integration Agreement With Boehringer Ingelheim
Chiesi Farmaceutici Enters Into Co-Promotion Agreement With Boeringher Ingelheim For Foster
Boehringer Ingelheim Enters Co-Marketing Agreement With VTU Technology
Boehringer Ingelheim Enters Into Co-Development Agreement With MacroGenics
Astellas Pharma Extends Co-Promotion Agreement With Nippon Boehringer Ingelheim
Boehringer Ingelheim Enters Into Collaboration Agreement With Micromet
Biota Holdings Terminates Co-Development Agreement With Boehringer Ingelheim
Sigma-Aldrich Enters Into Distribution Agreement With Boehringer Ingelheim
Eli Lilly Terminates Co-Development Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Co-Development Agreement With Priaxon
Licensing Agreements
AbbVie to Enter into Licensing Agreement with Boehringer Ingelheim
Boehringer Ingelheim Enters into Licensing Agreement with Vectron Biosolutions
Boehringer Ingelheim to Enter into Licensing Agreement with Hanmi Pharmaceuticals
Hydra Biosciences Enters into Licensing Agreement with Boehringer Ingelheim
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202
Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program
Zealand Pharma Enters into Licensing Agreement with Boehringer
Connexios Life Sciences Enters Into Licensing Agreement With Boehringer Ingelheim Sciences For CNX-012
Fibrostatin Enters into Licensing Agreement with Boehringer Ingelheim
BaroFold To Enter Into Licensing Agreement With Boehringer Ingelheim For PreEMT
Polyphor Enters Into Licensing Agreement With Boehringer Ingelheim For MacroFinder Drug Discovery Technology
AbGenomics Terminates Licensing Agreement With Boehringer Ingelheim For AbGn-168H
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen
Zealand Pharma Enters Into Licensing And Collaboration Agreement With Boehringer Ingelheim
Depomed Enters Into Licensing Agreement With Boehringer Ingelheim
f-star Biotechnologische Enters Into Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Fresenius Kabi Deutschland
Marinomed Biotechnologie Enters Into Licensing Agreement With Boehringer Ingelheim
Asset Transactions
Sanofi Plans to Acquire Consumer Healthcare Business of Boehringer Ingelheim
Evonik Completes Acquisition Of Resomer Business From Boehringer Ingelheim Pharma
Acquisition
Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma
Boehringer Ingelheim May Sell Roxane Labs
Soho Flordis International Acquires Ginsana From Pharmaton
Boehringer Ingelheim Acquires An Additional 33.6% Stake In SSP
Boehringer Ingelheim GmbH - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Key Facts, 2014
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Deals By Therapy Area, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Medical Devices Deals, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis
Boehringer Ingelheim To Acquire Global Rights To FX125L And Somatotaxin Portfolio From Funxional Therapeutics
Boehringer Ingelheim Plans To Acquire OTC Brands In India
Boehringer Ingelheim Acquires PDE2 Inhibitors Platform From biocrea
Boehringer Ingelheim Acquires Fremont Facility From Amgen
Pcovery Raises USD4 Million in Venture Financing
Eyevensys Raises Funds In Second Round Of Financing
ArmaGen Technologies Raises US$17 Million In Series A Financing
Boehringer May Enter into Agreement with AbbVie
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma
Boehringer Ingelheim Enters into Co-Development Agreement with MD Anderson Cancer Center
Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement
Boehringer Ingelheim Enters into Partnership with Circuit Therapeutics
Boehringer Ingelheim Terminates Agreement with Vitae Pharma
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics
Boehringer Ingelheim Pharma Enters into Research Agreement with Sutter Health
Artes Biotech Enters into Agreement with Boehringer Ingelheim
Boehringer Ingelheim Extends Agreement with VTU Technology
Boehringer Ingelheim Extends Research Agreement with BioMed X
Eli Lilly Amends Co-Promotion Agreement with Boehringer Ingelheim
Boehringer Ingelheim Terminates Co-Marketing Agreement with Pfizer for Spiriva
Hydra Biosciences Enters Into R&D Agreement With Boehringer Ingelheim
Crystal Biosciences Enters Into Agreement With Boehringer Ingelheim To Discover And Develop Therapeutic Antibodies
Circuit Therapeutics Enters Into Research Agreement With Boehringer Ingelheim For Drug Discovery
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim
Beactica Expands Drug Discovery Agreement With Boehringer Ingelheim
Diaxonhit Enters Into Research Agreement With Boehringer Ingelheim For Epitope Targets
Boehringer Ingelheim And Shanghai Zhangjiang Biotech Form R&D Joint Venture
Novation Pharma Enters into Research Agreement with Boehringer Ingelheim
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets
Eli Lilly Terminates Co-Development Agreement With Boehringer For LY2605541
Boehringer Ingelheim Enters Into Research Agreement With ETH Zurich
Ablynx Extends Co-development Agreement With Boehringer Ingelheim For Nanobody Therapeutics
Xencor Enters Into Co-Development Agreement With Boehringer Ingelheim For Biosuperior Monoclonal Antibodies
Eli Lilly Enters Into Co-Promotion Agreement With Boehringer Ingelheim For Humalog And Linagliptin
Nuevolution Enters Into Co-Development Agreement With Boehringer Ingelheim
Pfenex Enters Into Collaboration With Boehringer Ingelheim
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim
Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim
Hepregen Extends Technology Integration Agreement With Boehringer Ingelheim
Chiesi Farmaceutici Enters Into Co-Promotion Agreement With Boeringher Ingelheim For Foster
Boehringer Ingelheim Enters Co-Marketing Agreement With VTU Technology
Boehringer Ingelheim Enters Into Co-Development Agreement With MacroGenics
Astellas Pharma Extends Co-Promotion Agreement With Nippon Boehringer Ingelheim
Boehringer Ingelheim Enters Into Collaboration Agreement With Micromet
Biota Holdings Terminates Co-Development Agreement With Boehringer Ingelheim
Sigma-Aldrich Enters Into Distribution Agreement With Boehringer Ingelheim
Eli Lilly Terminates Co-Development Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Co-Development Agreement With Priaxon
AbbVie to Enter into Licensing Agreement with Boehringer Ingelheim
Boehringer Ingelheim Enters into Licensing Agreement with Vectron Biosolutions
Boehringer Ingelheim to Enter into Licensing Agreement with Hanmi Pharmaceuticals
Hydra Biosciences Enters into Licensing Agreement with Boehringer Ingelheim
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202
Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program
Zealand Pharma Enters into Licensing Agreement with Boehringer
Connexios Life Sciences Enters Into Licensing Agreement With Boehringer Ingelheim Sciences For CNX-012
Fibrostatin Enters into Licensing Agreement with Boehringer Ingelheim
BaroFold To Enter Into Licensing Agreement With Boehringer Ingelheim For PreEMT
Polyphor Enters Into Licensing Agreement With Boehringer Ingelheim For MacroFinder Drug Discovery Technology
AbGenomics Terminates Licensing Agreement With Boehringer Ingelheim For AbGn-168H
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen
Zealand Pharma Enters Into Licensing And Collaboration Agreement With Boehringer Ingelheim
Depomed Enters Into Licensing Agreement With Boehringer Ingelheim
f-star Biotechnologische Enters Into Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Fresenius Kabi Deutschland
Marinomed Biotechnologie Enters Into Licensing Agreement With Boehringer Ingelheim
Sanofi Plans to Acquire Consumer Healthcare Business of Boehringer Ingelheim
Evonik Completes Acquisition Of Resomer Business From Boehringer Ingelheim Pharma
Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma
Boehringer Ingelheim May Sell Roxane Labs
Soho Flordis International Acquires Ginsana From Pharmaton
Boehringer Ingelheim Acquires An Additional 33.6% Stake In SSP
Boehringer Ingelheim GmbH, Key Competitors
Boehringer Ingelheim GmbH, Key Employees
Boehringer Ingelheim GmbH, Subsidiaries

LIST OF FIGURES

Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Medical Devices Deals, 2010 to YTD 2016
Skip to top


Ask Your Question

Boehringer Ingelheim GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: